Benzinga | Jan 31, 2022 06:03AM EST

Ocuphire Presenting New Data And Updates On APX3330 And Nyxol Clinical Programs At Virtual Investor R&D Day

New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia

First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients enrolled

New masked data show favorable safety profile for oral APX3330 in diabetic patients

Advancing pre-commercial activities for Nyxol in RM with expected NDA filing late 2022 and potential market commercialization in 2023

Live R&D Day webinar featuring six leading ophthalmic KOLs today @ 10am ET